10-Q: Telomir Pharmaceuticals Q1 2026 Results: Merger Completed, Funding Secured

Telomir Pharmaceuticals reports reduced operating costs and net loss in Q1 2026, following the completion of its merger with TELI and securing future funding commitments.

Summary

• Telomir Pharmaceuticals reported a net loss of $990,947 for the three months ended March 31, 2026, a significant improvement from the $2,179,828 net loss in the same period of 2025.
• Total operating costs decreased by approximately $1.15 million to $1,041,336 in Q1 2026 from $2,187,782 in Q1 2025, driven by a substantial reduction in general and administrative expenses.
• Research and development expenses increased by $130,801 to $467,797 in Q1 2026 compared to $336,996 in Q1 2025.
• The company completed its merger with TELI Pharmaceuticals, Inc. on April 22, 2026, consolidating global rights to its lead candidate, Telomir-1 (Telomir-Zn).
• Bayshore Trust provided a $1.0 million cash contribution and committed up to an additional $4.0 million in equity funding, contingent on regulatory and clinical milestones for Telomir-1.
• As of March 31, 2026, the company had $5,560,511 in cash and cash equivalents, and expects these funds to be sufficient through the first quarter of 2027.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the continued net losses, substantial accumulated deficit, and the going concern warning, despite positive developments like the merger completion and secured funding commitments.

Positives

• Significant reduction in net loss to $990,947 in Q1 2026 from $2,179,828 in Q1 2025.
• Substantial decrease in total operating costs by $1,146,446, primarily due to lower general and administrative expenses.
• Completion of the TELI merger on April 22, 2026, consolidating global rights to Telomir-1 (Telomir-Zn).
• Secured $1.0 million in immediate funding from Bayshore Trust and a commitment for up to $4.0 million in future funding tied to development milestones.
• FDA clearance for an Investigational New Drug (IND) application for Telomir-Zn to evaluate its use in advanced or metastatic triple-negative breast cancer (TNBC).
• Cash and cash equivalents of $5,560,511 as of March 31, 2026, projected to fund operations through Q1 2027.

Negatives

• Continued net loss of $990,947 for the quarter.
• Accumulated deficit of $42,001,010 as of March 31, 2026.
• The company has no source of revenue and expects to continue generating losses.
• Substantial doubt exists about the company's ability to continue as a going concern for the next 12 months without additional funding.
• The company may need to curtail operations if additional capital cannot be raised.
• Stock-based compensation expense was $39,803 in Q1 2026, compared to $1,375,686 in Q1 2025, indicating a significant decrease in equity awards or valuation.

Risks

• The company's ability to fund ongoing operations and future clinical trials is dependent on obtaining significant additional external funding.
• There can be no assurance that any fundraising will be achieved on commercially reasonable terms, if at all.
• If the company is unable to raise additional capital or secure additional lending in the near future, management expects that the company will need to curtail its operations.
• The company is subject to risks common to pharmaceutical companies, including development by competitors, reliance on key personnel and third-party manufacturers, protection of proprietary technology, and compliance with regulatory requirements.
• The probability of success of product candidates is affected by clinical data, competition, manufacturing capability, and commercial viability.
• The company may never succeed in timely development and achieving regulatory approval for its product candidates.
• The company's ability to obtain and maintain regulatory approval for its product candidates.
• The company's ability to successfully commercialize and market its product candidates, if approved.
• The potential market size, opportunity, and growth potential for its product candidates, if approved.

Future Outlook

The company expects its cash and cash equivalents to be sufficient to fund its operations, development plans, and capital expenditures through the first quarter of 2027. However, it anticipates substantial increases in expenses as it advances pre-clinical activities and initiates clinical trials. The company plans to conduct a capital raise in the near future to assist in financing working capital needs. Management cannot provide assurance that the company will achieve profitable operations or become cash flow positive or raise additional debt and/or equity capital.

Management Comments

• "Our ability to fund ongoing operations and future clinical trials required for FDA approval is dependent on the Company's ability to obtain significant additional external funding in the near term."
• "Management expects that the Company will need to curtail its operations if the Company is unable to raise additional capital or secure additional lending in the near future."
• "The Company is currently evaluating the appropriate accounting treatment for the TELI Transaction and the Funding Commitment, including the allocation of purchase consideration, the classification of the funding commitments, and the related equity issuance accounting."
• "As a result of the Merger, the Company obtained exclusive worldwide rights to develop and commercialize Telomir-1 (Telomir-Zn), consolidating previously separated geographic rights within a single corporate entity."

Industry Context

StockSavvy.ai notes that Telomir Pharmaceuticals operates in the highly competitive and capital-intensive clinical-stage biotechnology sector. The company's focus on small-molecule therapeutics for cancer and age-related diseases aligns with significant industry trends, but the path to market is fraught with high R&D costs, regulatory hurdles, and the need for substantial ongoing funding. The recent merger and secured funding are critical steps in navigating these challenges, particularly in light of the company's current lack of revenue and ongoing net losses.

Comparison to Industry Standards

• Many clinical-stage biotechnology companies, like Telomir, rely heavily on equity financings and strategic partnerships to fund their operations due to the absence of product revenue. Companies such as Moderna and BioNTech, prior to their major breakthroughs, also experienced periods of significant cash burn and reliance on external funding.
• The average cash burn rate for clinical-stage biotechs can vary widely, but Telomir's Q1 2026 net cash used in operating activities of $1.8 million is within a range seen for companies at a similar stage of development, especially those advancing a lead candidate through IND and early clinical phases.
• The successful completion of a merger to consolidate intellectual property and development rights, as Telomir did with TELI, is a common strategy to streamline operations and enhance the value proposition for future investors or partners. This is often seen in the industry to create a more focused and attractive entity.
• The reliance on related-party financing and significant stockholders (Bayshore Trust, Starwood Trust) is not uncommon in early-stage biotech, though it can also present governance and valuation complexities. Industry benchmarks often show a mix of institutional and strategic investor involvement at this stage.

Legal Proceedings

• Currently, no legal proceedings, government actions, administrative actions, investigations, or claims are pending against the company or involve the company that, in the opinion of management, could reasonably be expected to have a material adverse effect on its business and financial condition.
• The company anticipates expending significant financial and managerial resources in the defense of its intellectual property rights and against claims of infringing third-party intellectual property rights.

Related Party Transactions

• The company licenses intellectual property rights for Telomir-1 from MIRALOGX, LLC, an entity controlled by a trust established by the company's founder. MIRALOGX is a related party and a greater-than-10% stockholder.
• Under license agreements with MIRALOGX, the company is obligated to pay an 8% royalty on net sales of licensed products and a minimum annual royalty of $250,000 once revenue is generated.
• As of March 31, 2026, amounts due to related parties totaled $344,826.
• In December 2025, the CEO, Erez Aminov, advanced $155,518 to the company for payroll withholding taxes, which was repaid in January 2026.
• Accrued compensation of $417,470 owed to CEO Erez Aminov as of December 31, 2025, was fully repaid in January 2026.
• During the three months ended March 31, 2026, the company incurred $26,592 of intellectual property development costs paid on its behalf by MIRALOGX.
• Bayshore Trust, affiliated with the largest stockholder, invested $3 million in equity financing in 2025, issuing 1,000,000 shares at $3.00 per share.
• Starwood Trust, a separate related party trust, has a $5 million unsecured Promissory Note and Loan Agreement with the company, with no amounts borrowed as of March 31, 2026.
• MIRA Pharmaceuticals, Inc., a related party, holds approximately 10% of the company's outstanding common stock.

Stakeholder Impact

• Shareholders: The completion of the TELI merger consolidates rights to Telomir-1, potentially increasing future value. However, the ongoing net losses and going concern warning present significant risks to shareholder value.
• Employees: The company's ability to continue operations and fund future development is critical for employee job security. Stock-based compensation has decreased significantly year-over-year.
• Creditors: The company's financial condition and reliance on future funding may impact its ability to meet obligations, though no material non-cancellable contractual obligations were noted.
• Suppliers: The company's ability to continue operations ensures ongoing business for its suppliers, particularly contract research organizations and manufacturers.

Next Steps

• Advance Telomir-1 (Telomir-Zn) into and through clinical trials.
• Pursue regulatory approvals for Telomir-1.
• Evaluate opportunities to acquire or in-license additional product candidates and technologies.
• Continue preclinical research for Telomir-1 across multiple disease areas.
• Seek additional debt and/or equity financings to fund operations.
• The company anticipates accounting for the TELI Transaction as an asset acquisition.

Key Dates

Recommendation

The company has made progress with the TELI merger and secured future funding commitments, which are positive developments. However, the continued net losses, substantial accumulated deficit, and the explicit warning about the ability to continue as a going concern present significant risks. While the lead candidate has IND clearance, commercialization is distant. Therefore, a 'hold' recommendation is appropriate, suggesting investors monitor future financing efforts and clinical trial progress closely without initiating new positions or significantly increasing existing ones until greater financial stability and de-risking of the development pipeline are evident.

Keywords

Telomir Pharmaceuticals, Form 10-Q, Quarterly Report, Biotechnology, Clinical Stage, Telomir-1, Telomir-Zn, Triple-Negative Breast Cancer, IND Application, Merger, TELI Pharmaceuticals, Bayshore Trust, Funding Commitment, SEC Filing, Financial Statements